US2016002630A1PendingUtilityA1
Bispecific Antisense Oligonucleotides that Inhibit IGFBP-2 and IGFBP-5 and Methods of Using Same
Est. expiryJan 17, 2022(expired)· nominal 20-yr term from priority
A61K 38/00C12N 2310/11A61K 31/713C12N 2310/51A61P 35/04C12N 2310/3519A61P 35/00C12N 15/113C07K 2319/00C12N 2310/111C12N 15/11A61K 48/00
66
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
Bispecific antisense oligonucleotides which consist essentially of a sequence of bases that is complementary to portions of both the gene encoding human IGFBP-2 and the gene encoding human IGFBP-5 are useful in as antisense therapeutics in the treatment of endocrine-regulated cancers.
Claims
exact text as granted — not AI-modified1 - 18 . (canceled)
19 . A bispecific antisense oligodeoxynucleotide wherein the base sequence of the oligodeoxynucleotide consists of SEQ. ID NO. 5.
20 . A pharmaceutical composition comprising a bispecific antisense oligodeoxynucleotide and a pharmaceutically acceptable carrier, wherein the base sequence of the bispecific antisense oligodeoxynucleotide consists of SEQ ID NO. 5, and wherein the bispecific antisense oligonucleotide is present in the composition at a concentration of 50 nM or greater.
21 . The composition of claim 20 , wherein the pharmaceutically acceptable carrier is a lipid carrier.
22 . The composition of claim 20 , wherein the bispecific antisense oligodeoxynucleotide is present in the composition at a concentration of 50 to 500 nM.
23 . The composition of claim 22 , wherein the pharmaceutically acceptable carrier is a lipid carrier.Join the waitlist — get patent alerts
Track US2016002630A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.